Cystic Fibrosis Trial, Recruiting (NCT07202910)

Cystic Fibrosis Trial, Recruiting NCT07202910 Sponsor: Sahlgrenska University Hospital Condition: Cystic Fibrosis

Printed from Voxsanity (voxsanity.com.au) — NCT07202910 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cystic Fibrosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Children aged 0 to 18 years who are already scheduled to have a liver biopsy at Queen Silvia Children's Hospital as part of their normal medical care
Children who have a suspected or confirmed liver condition of any kind
Children (and/or their parents) who agree to take part in the study
Children aged 0 to 18 years who are scheduled for a kidney biopsy may also be eligible to join as a comparison group
Parents or guardians of children in the comparison group who agree to take part in the study

Who may not be able to join:

Children where there are technical difficulties that would prevent the study measurements from being taken properly (confirm with trial site)
Anyone who is unable to fully understand the consent forms and information provided about the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hanna Hebelka, Institute of clinical sciences, Sahlgrenska Academy, Gothenburg University

Phone: +46705667867

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07202910

Sponsor: Sahlgrenska University Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Cystic Fibrosis

Trial contact: +46705667867

More information: https://clinicaltrials.gov/study/NCT07202910

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Children aged 0 to 18 years who are already scheduled to have a liver biopsy at Queen Silvia Children's Hospital as part of their normal medical care
Children who have a suspected or confirmed liver condition of any kind
Children (and/or their parents) who agree to take part in the study
Children aged 0 to 18 years who are scheduled for a kidney biopsy may also be eligible to join as a comparison group
Parents or guardians of children in the comparison group who agree to take part in the study

Who may not be able to join:

Children where there are technical difficulties that would prevent the study measurements from being taken properly (confirm with trial site)
Anyone who is unable to fully understand the consent forms and information provided about the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Sahlgrenska University Hospital

Registry

ClinicalTrials.gov

Start date

28 March 2019

Est. completion

1 March 2030

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Diagnostic accuracy of ultrasound-based liver biomarkers (SWE, SWD, ATI) (STUDY 1); Longitudinal change in SWE/SWD/ATI biomarkers before and after treatment with CFTR modulators, (Study 2A - Children with Cystic Fibrosis); Change in liver biomarkers measured by SWE and SWD during routine ultrasound surveillance post-liver transplantation. (Study 2b); Detection of early liver damage using SWE, SWD, and ATI (Attenuation Imaging) in children with intestinal failure. (Study 2c); Change in SWE/SWD/ATI biomarkers following obesity treatment (GLP-1 analogues or bariatric surgery) (Study2d); Correlati...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov